Verona Pharma has announced positive top-line data from its US pharmacokinetic (PK) trial with RPL554. The results indicate that nebulised RPL554 delivers an optimal dose and is an appropriate form of administration for patients with COPD and other respiratory disorders. RPL554 continues to deliver positive data, demonstrating an attractive profile with its combined bronchodilator and anti-inflammatory properties. Verona Pharma commenced its Phase IIb trial evaluating RPL554 as maintenance treat ....
27 Sep 2017
N+1 Singer - Verona Pharma - Positive top-line data from US PK trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Verona Pharma - Positive top-line data from US PK trial
Verona Pharma plc Sponsored ADR (VRNA:NAS) | 0 0 0.0%
- Published:
27 Sep 2017 -
Author:
Sheena Berry -
Pages:
3
Verona Pharma has announced positive top-line data from its US pharmacokinetic (PK) trial with RPL554. The results indicate that nebulised RPL554 delivers an optimal dose and is an appropriate form of administration for patients with COPD and other respiratory disorders. RPL554 continues to deliver positive data, demonstrating an attractive profile with its combined bronchodilator and anti-inflammatory properties. Verona Pharma commenced its Phase IIb trial evaluating RPL554 as maintenance treat ....